---
title: "ADC Therapeutics SA Updates Corporate Strategy and Financial Outlook"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/272279996.md"
description: "ADC Therapeutics SA has updated its corporate strategy and financial outlook as of January 12, 2026. The company projects preliminary FY2025 net revenue of approximately $73M, an increase from $69M in FY2024. The focus will shift towards expanding ZYNLONTA, with a cash runway expected until 2028. The LOTIS-7 trial reported an 89.8% overall response rate and a 77.6% complete response rate. ADC plans to discontinue its solid-tumor preclinical pipeline to prioritize ZYNLONTA and has raised $160M through equity offerings, with an estimated cash balance of $261M."
datetime: "2026-01-12T13:43:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272279996.md)
  - [en](https://longbridge.com/en/news/272279996.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272279996.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/272279996.md) | [繁體中文](https://longbridge.com/zh-HK/news/272279996.md)


# ADC Therapeutics SA Updates Corporate Strategy and Financial Outlook

**On January 12, 2026, ADC Therapeutics SA released an updated corporate presentation highlighting strategic shifts and financial projections.**

**Key Highlights:**

-   Preliminary FY2025 net revenue of ~$73M, up from $69M in FY2024.
-   Strategic focus on ZYNLONTA expansion, with a cash runway expected to last until 2028.
-   LOTIS-7 trial shows 89.8% ORR and 77.6% CR, indicating strong efficacy.
-   Company plans to discontinue solid-tumor preclinical pipeline to prioritize ZYNLONTA.
-   Equity offerings raised $160M, with an estimated cash balance of ~$261M.

Original SEC Filing: ADC Therapeutics SA \[ ADCT \] - 8-K - Jan. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### 相关股票

- [ADC Therapeutics SA (ADCT.US)](https://longbridge.com/zh-CN/quote/ADCT.US.md)

## 相关资讯与研究

- [Is Agree Realty (ADC) Offering Value After Mixed Returns And Conflicting DCF And P/E Signals](https://longbridge.com/zh-CN/news/279282065.md)
- [ADC Therapeutics Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million](https://longbridge.com/zh-CN/news/271983442.md)
- [Does Zymeworks (ZYME) Pan-RAS ADC Push Reveal a Durable Edge in Targeted Oncology?](https://longbridge.com/zh-CN/news/279730661.md)
- [Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting | ZYME Stock News](https://longbridge.com/zh-CN/news/279491368.md)
- [Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data](https://longbridge.com/zh-CN/news/279127766.md)